HARMONY BIOSCIENCES HOLDINGS, INC. Interest Expense
HARMONY BIOSCIENCES HOLDINGS, INC. (HRMY) reported Interest Expense of $4.54 million for the 3-month period ending 2024-03-31, per its 10-Q filed 2024-04-30.
Discontinued › Expense Statement
us-gaap:InterestExpense · last filed 2024-04-30
- HARMONY BIOSCIENCES HOLDINGS, INC. interest expense for the quarter ending 2024-03-31 was $4.54M, a 20.87% decline year-over-year.
- HARMONY BIOSCIENCES HOLDINGS, INC. interest expense for the quarter ending 2023-03-31 was $5.73M.
- HARMONY BIOSCIENCES HOLDINGS, INC. interest expense for fiscal 2023 was $23.76M, a 26.40% increase from fiscal 2022.
- HARMONY BIOSCIENCES HOLDINGS, INC. interest expense for fiscal 2022 was $18.80M, a 22.32% decline from fiscal 2021.
- HARMONY BIOSCIENCES HOLDINGS, INC. interest expense for fiscal 2021 was $24.19M.
| Period end | Interest Expense 3 month | Interest Expense 12 month |
|---|---|---|
| 2024-03-31 | $4.54M 10-Q · filed 2024-04-30 | |
| 2023-12-31 | $23.76M 10-K · filed 2024-02-22 | |
| 2023-03-31 | $5.73M 10-Q · filed 2024-04-30 | |
| 2022-12-31 | $18.80M 10-K · filed 2024-02-22 | |
| 2021-12-31 | $24.19M 10-K · filed 2024-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |